2022 — a turning point for US biosimilars?
![](/46/pdcnewsitem/11/62/66/R5HTRK@0.1x.jpg)
Cardinal Health says the majority of healthcare providers are keen to use biosimilars despite current market challenges
2022 has been tipped a watershed year for biosimilars in the US by Cardinal Health, who has today published its first biosimilars report, which combines industry data on biosimilar use and payer coverage with survey data from healthcare providers, and views from leading physicians and experts on biosimilars.
The publication, 2022 Biosimilars Report: The US Journey and Path Ahead, not only provides insights on where biosimilar adoption currently stands, it also predicts what the industry can expect in 2022 and beyond as biosimilars come to market in key disease categories such as diabetes and immunology. In addition, the report highlights the pipeline of biosimilars expected to launch in the US during the period 2022–2029.
Key findings, which are based on "robust" data also included in the report, reveal that although biosimilar market challenges remain, the majority of healthcare providers are keen to use biosimilars to widen patient access and to drive more affordable care for their patients.
Throughout 2020 and 2021, Cardinal Health conducted biosimilar surveys with more than 320 oncologists, 100 rheumatologists, 100 retina specialists, 50 endocrinologists and primary care physicians treating diabetes, and 115 retail pharmacists.
The research includes results from a new insulin biosimilar survey with retail pharmacists showing that only about 40% feel very prepared to discuss biosimilars with patients, yet three-quarters of surveyed physicians and pharmacists agreed that insulin biosimilars will lower the cost of diabetes care.
The same survey also shows that only 20% of retain pharmacists say they are very familiar with the FDA's interchangeability designation, which enables them to substitute insulin biosimilars in place of reference biologics, indicating a significant need for further education among pharmacists.
Furthermore, the number of biologics facing biosimilar competition is expected to double by 2025, which is positive news for patients.
![Cardinal Health](https://www.cphi-online.com/c272449th_S-comp272449.jpg)
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance